RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07264816, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 10

    Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;

    Exclusion criterion 3

  3. ECOG performance status score of 0 or 1;

    Inclusion criterion 9

  4. Must have at least one measurable lesion meeting the RECIST v1.1 criteria;

    Inclusion criterion 8

  5. Diagnosed with other primary malignancies within 5 years before the first dose;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07264816, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • No gender restrictions;
  • Age at the time of signing the informed consent form ≥18 years and ≤75 years;
  • Expected survival time ≥3 months;
  • Patients with locally advanced or metastatic non-squamous non-small cell lung cancer;
  • Confirmed known HER2 overexpression;
  • Agree to provide archived tumor tissue specimens from primary or metastatic lesions within the past 2 years;
  • Must have at least one measurable lesion meeting the RECIST v1.1 criteria;
  • ECOG performance status score of 0 or 1;
  • Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
  • No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  • Organ function levels must meet the requirements;
  • For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, serum pregnancy must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should take adequate and highly effective contraception throughout the treatment cycle and for 7 months after the end of treatment.

Exclusion Criteria:

  • Underwent surgical treatment, radical radiotherapy, immunotherapy, etc., within 4 weeks before the first dose or within 5 half-lives;
  • Pathology indicates non-small cell carcinoma containing small cell carcinoma components and sarcomatoid carcinoma;
  • Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;
  • History of severe cardiovascular or cerebrovascular diseases within the past 6 months before screening;
  • Concurrent pulmonary disease leading to severe impairment of lung function;
  • QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  • Diagnosed with other primary malignancies within 5 years before the first dose;
  • Poorly controlled hypertension;
  • History of non-infectious ILD requiring steroid treatment, or currently suffering from ILD/interstitial pneumonia, etc.;
  • Patients with central nervous system metastases, carcinomatous meningitis, and/or spinal cord compression;
  • Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-M07D1, pembrolizumab, or any excipient components;
  • Required systemic corticosteroid or immunosuppressive therapy within 2 weeks before the study administration;
  • Patients with massive serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;
  • New deep vein thrombosis within 14 days, excluding patients with venous filters implanted;
  • Systemic severe infection within 4 weeks before screening;
  • Active autoimmune diseases and inflammatory diseases;
  • Human immunodeficiency virus antibody positivity, active hepatitis B virus infection, or hepatitis C virus infection;
  • History of allogeneic stem cell, bone marrow, or organ transplantation;
  • Presence of severe neurological or psychiatric disorders;
  • Presence of other severe physical or laboratory abnormalities, poor compliance, etc., which may increase the risk of participation in the study, interfere with study results, or patients deemed unsuitable for participation in the study by the investigator.

Quoted from ClinicalTrials.gov, NCT07264816, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07264816, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07264816